Good day,
Thank you for subscribing to the Earnings360 newsletter, your daily source for quarterly earnings news and updates.
Each morning edition contains a wrap-up of today's pre-market earnings announcements and yesterday's earnings announcements after the closing bell.
Before we send you your first edition, please take a moment to confirm your subscription below. We will not be able to send your newsletter until you confirm your subscription.
Confirm Your Subscription Here
The Earnings360 Team
Featured News from MarketBeat Media Abbott Laboratories' October Price Plunge Is a Signal to BuyWritten by Thomas Hughes. Published 10/17/2025. 
Key Points - Abbott Laboratories' Q3 results did not catalyze a rally but also did not provide a reason to sell.
- Margin is solid, growth is present, and the capital return outlook is reliable.
- Analyst and institutional trends suggest these influential market groups will buy ABT on the dip.
Abbott Laboratories (NYSE: ABT)'s October price plunge is a buy signal, as analyst and institutional trends indicate further buying. MarketBeat data show rising analyst coverage, with newly initiated ratings appearing within days of the Q3 earnings release. Coverage is increasing, sentiment has firmed over the past two quarters, and price targets are moving higher. The consensus forecast called for roughly a 10% gain ahead of the release—enough to reach a new all-time high—while the high-end range implies about another 10% upside. George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the last 40 years. Now he's stepping forward with an even bigger prediction about what's being built in the Arizona desert.
He believes 3 little-known companies will explode when a bombshell announcement just days from now. Smart investors are already positioning themselves. Click here to see what's coming before the story goes mainstream. The institutional group has been consistently buying this healthcare stock throughout the year. MarketBeat's data show institutions purchased roughly $1.50 for every $1.00 sold over the past 12 months, with activity accelerating in the back half to about $3.25 bought for each $1.00 sold as of mid-October. Institutions now own roughly 75% of the shares, providing a solid support base and a tailwind for price action reflected in the charts. 
The ABT chart shows a market in a long-term uptrend, currently consolidating before its next significant move. The monthly view shows the stock pulling back from recent peaks but still in rebound mode, forming a bullish flag pattern following the October 2023 trend-line bounce and the price reversal confirmed earlier this year. Abbott's price action may consolidate at this level through year-end, but it appears positioned to reach higher prices in 2026, supported by growth, earnings quality, and capital returns. A move to new highs would be meaningful, potentially setting a target near $30—roughly 30% upside from current levels. Abbott Laboratories Q3 Release Is No Reason to Sell This Stock Abbott Laboratories' Q3 release was tepid relative to analysts' consensus, but it did not justify selling the stock. Revenue growth missed the consensus by a narrow 0.17% margin, but the company still reported 6.9% revenue growth and maintained healthy margins. Foreign exchange, which has been a headwind for many S&P 500 companies, turned into a tailwind for Abbott, positively impacting both revenue and earnings during the quarter. Revenue growth was driven by strength in the U.S. and international markets, led by a 9.9% increase in international sales and growth across three primary reporting segments. Diagnostics was the weak link, down 7.8% organically, largely reflecting lower COVID-19–related sales that are not core to the ongoing business. Other segments performed well, with Medical Devices delivering 12.5% organic growth and Established Pharmaceuticals rising 7.1%. The margin picture is constructive. The company widened its adjusted operating margin by 40 basis points, producing leveraged income growth. Operating earnings increased 10.6% while net income grew 7.5%, leaving adjusted EPS at $1.30—in line with expectations and up about 7.45% year over year. The key takeaway is that Abbott's diversified model supports growth and solid margins, underpinning its capital return prospects. Abbott Laboratories' Dividend Is Reliable and Growing Abbott Laboratories' dividend is reliable and is expected to grow at a high-single- to low-double-digit pace for the foreseeable future. The company is a Dividend King with over 50 consecutive years of annual increases, pays only about 45% of its earnings guidance as dividends, and projects meaningful earnings growth. Long-term consensus expects Abbott to grow earnings at a low-double-digit pace for at least the next five years, which should comfortably support dividend increases without impairing the company's ability to invest in growth. Its diversified product portfolio—spanning diagnostics, medical devices, nutrition, and branded generics—provides multiple revenue streams that help buffer against sector-specific slowdowns. With a strong balance sheet and consistent cash flow, Abbott remains well-positioned to sustain both growth investments and rising shareholder returns.
| 
